{"schema_version":"secwatch.filing_event.v1","accession":"0001108205-25-000079","form_type":"8-K","ticker":"CRIS","cik":"0001108205","company_name":"CURIS INC","filed_at":"2025-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.359516+00:00","generated_at":"2026-05-17T20:25:04.725611+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Curis Q2 2025 net loss $8.6M; cash runway extended to Q1 2026 via $6M offering","bullets":["Net loss $8.6M ($0.68/sh) vs $11.8M ($2.03/sh) in Q2 2024; revenue $2.7M from Erivedge royalties.","Cash and equivalents $10.1M at June 30, 2025; July 2025 offerings added ~$6M net proceeds.","TakeAim Lymphoma study enrolling PCNSL patients to support US/EU accelerated approval; data expected later 2025.","Adding proof-of-concept CLL study of emavusertib + BTKi in 20-30 R/R patients; enrollment to begin later 2025.","TakeAim Leukemia Phase 1/2 enrollment complete; designing registrational trial vs gilteritinib in R/R AML."],"urls":{"canonical":"https://secwatch.observer/filing/0001108205-25-000079","json":"https://secwatch.observer/filing/0001108205-25-000079.json","markdown":"https://secwatch.observer/filing/0001108205-25-000079.md","text":"https://secwatch.observer/filing/0001108205-25-000079.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1108205/000110820525000079/0001108205-25-000079-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1108205/000110820525000079/cris-20250805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T20:25:04.725611+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}